Timothy Rolph Akero Therapeutics, Inc. (AKRO) insider trading activity

Timothy Rolph is Chief Scientific Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 167,124 shares of AKRO, which is worth approximately $8.61 Million. The most recent transaction as insider was on Jul 07, 2025, when has been sold 12,500 shares (Common Stock) at a price of $51.85 per share, resulting in proceeds of $648,125. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 167K

1.53% 3M change

7.79% 12M change

Total Value Held $8.61 Million

Timothy Rolph Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 07 2025	SELL Open market or private sale	$648,125 $51.85 p/Share	12,500 Reduced 6.96%	167,124 Common Stock
Jul 07 2025	BUY Exercise of conversion of derivative security	$263,625 $21.09 p/Share	12,500 Added 6.51%	179,624 Common Stock
Jun 30 2025	BUY Grant, award, or other acquisition	$21,244 $23.87 p/Share	890 Added 0.53%	167,124 Common Stock
Jun 18 2025	SELL Open market or private sale	$61,914 $54.84 p/Share	1,129 Reduced 0.67%	166,234 Common Stock
Jun 10 2025	SELL Open market or private sale	$127,332 $54.0 p/Share	2,358 Reduced 1.39%	167,363 Common Stock
Jun 06 2025	SELL Open market or private sale	$1,376,000 $55.04 p/Share	25,000 Reduced 12.84%	169,721 Common Stock
Jun 06 2025	BUY Exercise of conversion of derivative security	$527,500 $21.1 p/Share	25,000 Added 11.38%	194,721 Common Stock
Jun 05 2025	SELL Open market or private sale	$670,125 $53.61 p/Share	12,500 Reduced 6.86%	169,721 Common Stock
Jun 05 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 6.42%	182,221 Common Stock
May 06 2025	SELL Open market or private sale	$544,250 $43.54 p/Share	12,500 Reduced 6.86%	169,721 Common Stock
May 06 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 6.42%	182,221 Common Stock
Apr 24 2025	SELL Open market or private sale	$256,437 $41.03 p/Share	6,250 Reduced 3.55%	169,721 Common Stock
Apr 24 2025	BUY Exercise of conversion of derivative security	$131,875 $21.1 p/Share	6,250 Added 3.43%	175,971 Common Stock
Apr 07 2025	SELL Open market or private sale	$228,500 $36.56 p/Share	6,250 Reduced 3.55%	169,721 Common Stock
Apr 07 2025	BUY Exercise of conversion of derivative security	$131,875 $21.1 p/Share	6,250 Added 3.43%	175,971 Common Stock
Mar 12 2025	SELL Open market or private sale	$23,158 $44.88 p/Share	516 Reduced 0.3%	169,721 Common Stock
Mar 05 2025	SELL Open market or private sale	$558,125 $44.65 p/Share	12,500 Reduced 6.84%	170,237 Common Stock
Mar 05 2025	BUY Exercise of conversion of derivative security	$263,750 $21.1 p/Share	12,500 Added 6.4%	182,737 Common Stock
Feb 05 2025	SELL Open market or private sale	$1,061,812 $56.63 p/Share	18,750 Reduced 9.92%	170,237 Common Stock
Feb 05 2025	BUY Exercise of conversion of derivative security	$395,625 $21.1 p/Share	18,750 Added 9.03%	188,987 Common Stock
Jan 27 2025	SELL Open market or private sale	$1,743,125 $55.78 p/Share	31,250 Reduced 15.51%	170,237 Common Stock
Jan 27 2025	BUY Exercise of conversion of derivative security	$640,312 $20.49 p/Share	31,250 Added 13.43%	201,487 Common Stock
Jan 07 2025	SELL Bona fide gift	-	14,000 Reduced 7.6%	170,237 Common Stock
Dec 26 2024	SELL Bona fide gift	-	14,100 Reduced 7.11%	184,237 Common Stock
Dec 17 2024	SELL Open market or private sale	$118,180 $31.1 p/Share	3,800 Reduced 2.09%	178,337 Common Stock

Timothy Rolph

Chief Scientific Officer

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account